Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 7/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717505 | 0.94 | BRS3 (0.61) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| Ufiprazole SCHEMBL3186458 | 0.84 | BRS3 (0.71) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| Ufiprazole SCHEMBL3180530 | 0.84 | BRS3 (0.76) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3185356 | 0.84 | BRS3 (0.58) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| Ufiprazole SCHEMBL3170203 | 0.83 | BRS3 (0.74) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13068890 | 0.80 | BRS3 (0.70) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13645453 | 0.79 | SENP1 (0.37) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| Ufiprazole SCHEMBL662986 | 0.78 | BRS3 (0.84) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| Ufiprazole SCHEMBL29455226 | 0.78 | BRS3 (0.84) | BRS3HTTCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7851921 | 0.77 | BRS3 (0.66) | BRS3HTTCYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885HTT 1388/4885CYP2D6 757/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885HTT 1388/4885CYP2D6 757/4885 |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | ATP4A, ATP6V1G1, ATP6V1E1 | BRS3 2346/4885HTT 1388/4885CYP2D6 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.